Cargando…

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials

BACKGROUND: Angiogenesis inhibitors showed activity in ovarian cancer, but preliminary data could not accurately reflect the survival benefit. We thus did a systematic review and meta-analysis of randomized controlled trials to reassess the efficacy and safety of angiogenesis inhibitors combined wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haihong, Xu, Tie, Zheng, Lifen, Li, Guiling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Ovarian Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976222/ https://www.ncbi.nlm.nih.gov/pubmed/29561301 http://dx.doi.org/10.1097/IGC.0000000000001258

Ejemplares similares

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers
por: Sölétormos, György, et al.
Publicado: (2016)

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016)

Cellular Senescence in the Treatment of Ovarian Cancer
por: Wang, Zehua, et al.
Publicado: (2018)

Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
por: Rizzuto, Ivana, et al.
Publicado: (2015)

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
por: Colombo, Nicoletta, et al.
Publicado: (2017)

Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism
por: Sakurai, Manabu, et al.
Publicado: (2017)

The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)

Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer
por: Kleppe, Marjolein, et al.
Publicado: (2015)

Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a “Molecular Second Look”
por: Schwartz, Melissa, et al.
Publicado: (2018)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

Differential effects of thymoquinone on lysophosphatidic acid-induced oncogenic pathways in ovarian cancer cells
por: Ha, Ji Hee, et al.
Publicado: (2020)

Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario
por: McGee, Jacob, et al.
Publicado: (2017)

Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: In silico analysis and literature review of the anti-cancer pathways involved
por: Vallino, Letizia, et al.
Publicado: (2020)

High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension
por: Sakurai, Manabu, et al.
Publicado: (2015)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma
por: Skirnisdottir, Ingiridur, et al.
Publicado: (2015)

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
por: Oza, Amit M., et al.
Publicado: (2017)

Short-term Outcomes and Pregnancy Rate After Laparoscopic Fertility-Sparing Surgery for Borderline Ovarian Tumors: A Single-Institute Experience
por: Zhao, Jianguo, et al.
Publicado: (2018)

Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study
por: Leiserowitz, Gary S., et al.
Publicado: (2017)

Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center
por: Alwazzan, Ahmad Bakr, et al.
Publicado: (2015)

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2018)

Recent advances in systemic treatments for ovarian cancer
por: Banerjee, Susana, et al.
Publicado: (2012)

New ways of assessing ovarian cancer response: metabolic imaging and beyond
por: Rockall, Andrea, et al.
Publicado: (2012)

Updates on fluorescent probes and open‐field imaging methods for fluorescence‐guided cytoreductive surgery for epithelial ovarian cancer: A review
por: Sun, Chongen, et al.
Publicado: (2022)

High co‐expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer
por: Wu, Xiaodong, et al.
Publicado: (2022)

NOTCH signalling in ovarian cancer angiogenesis
por: Perez-Fidalgo, Jose Alejandro, et al.
Publicado: (2020)

A radiomic nomogram based on arterial phase of CT for differential diagnosis of ovarian cancer
por: Hu, Yumin, et al.
Publicado: (2021)

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials
por: Shao, Fengping, et al.
Publicado: (2020)

The Prognostic Significance of Adjuvant Chemotherapy in Adult Ovarian Granulosa Cell Tumors: A Systematic Review and Meta-analysis
por: Zhuang, Yuan, et al.
Publicado: (2023)

The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Zhuang, Yuan, et al.
Publicado: (2023)

Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience
por: Pandey, Avinash, et al.
Publicado: (2016)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

Ovarian cancer: state of the art and perspectives of clinical research
por: Boussios, Stergios, et al.
Publicado: (2020)

The effect of LTA gene polymorphisms on cancer risk: an updated systematic review and meta- analysis
por: Li, Jingdong, et al.
Publicado: (2020)

Meta-analysis of randomized controlled trials on vitamin D supplement and cancer incidence and mortality
por: Zhang, Xinran, et al.
Publicado: (2019)

Metformin and ovarian cancer: the evidence
por: Urpilainen, Elina, et al.
Publicado: (2020)

RoBERTa-Assisted Outcome Prediction in Ovarian Cancer Cytoreductive Surgery Using Operative Notes
por: Laios, Alexandros, et al.
Publicado: (2023)

Current practices on genetic testing in ovarian cancer
por: Fostira, Florentia, et al.
Publicado: (2020)

Current and future immunotherapy approaches in ovarian cancer
por: Demircan, Nazım Can, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c4pct1gmfsath4j039ti9k8rqe